BioSpace News Archive

Dose Escalation Complete; Single-Agent VT1021 Demonstrating Favorable Safety Profile and Early Signals of Clinical Activity

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Breast Cancer Research today announced the publication of an electronic poster with clinical data from the AWARE-1 window-of-opportunity breast cancer study at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded Hong Kong Patent No. 1188285 entitled, METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION.

OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020) taking place virtually November 9 to 14

Positive interim analysis data from the TOPAZ Phase 2 trial demonstrated proof-of-concept for apitegromab (SRK-015) in patients with Type 2 and Type 3 Spinal Muscular Atrophy

Echosens, a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert in the United States, a comprehensive non-invasive solution for advanced liver disease management.

- Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021 - Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars - Today announced additional in vivo preclinical data supporting the development of KB407 in cystic fibrosis - Strong balance sheet with cash, cash equivalents and short-term investments of $286.4 million as of September 30, 2020

OncoNano Medicine, Inc. today announced positive results from its preclinical study of ONM-400, a novel interleukin-2 (IL-2) encapsulating pH-activated nanoparticle that targets metabolic acidosis of cancer. ONM-400 employs OncoNano’s ON-BOARD TM platform designed to provide tumor specific delivery of a variety of cancer th

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company, will present preclinical data evaluating IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) for the treatment of solid tumors, at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (S

Eko, a cardiopulmonary digital health company, today announced $65 million in Series C funding led by Highland Capital Partners and Questa Capital, with participation from Artis Ventures, DigiTx Partners, NTTVC, 3M Ventures, and other new and existing investors.